Summary by Moomoo AI
CKLife Sciences announced in its mid-year performance report for 2024 that for the six months ended June 30, 2024, the company recorded unaudited attributable profit to shareholders of approximately HKD one million, down 97% from the same period last year. Profit before tax was HKD 174.5 million, but most of it was offset by financial costs. The board of directors decided not to distribute interim dividends. The company also announced the sale of Balranald vineyard land and water permits in Australia, with expected sales proceeds of approximately AUD 8,200,000. CKLife Sciences focuses on the research and development of cancer therapy and early detection programs, as well as investments in artificial intelligence cancer vaccine discovery platforms. The company's health product business has remained stable, while its agriculture-related business has suffered from high inventories and demand pressures, resulting in lower profits than last year. Looking ahead, the company will continue to invest in medical and diagnostic research fields and remain optimistic about improving business performance in the second half of the year.
